Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Esperion Therapeutics revenue
Esperion Therapeutics's revenue is $332.3 million.
What is Esperion Therapeutics's revenue?
- Esperion Therapeutics's revenue growth from 2019 to 2024 is 123.99%.
- Esperion Therapeutics has 218 employees, and the revenue per employee ratio is $1,524,376.
- Esperion Therapeutics's peak quarterly revenue was $212.2M in 2020(q2).
- Esperion Therapeutics peak revenue was $332.3M in 2024.
- Esperion Therapeutics annual revenue for 2023 was 116.3M, 54.14% growth from 2022.
- Esperion Therapeutics annual revenue for 2024 was 332.3M, 185.66% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Esperion Therapeutics historical revenue
Esperion Therapeutics's peak revenue was $332.3M in 2024. The peak quarterly revenue was $212.2M in 2020(q2).
Esperion Therapeutics's revenue increased from $148.4m in 2019 to $332.3M currently. That's a 123.99% change in annual revenue.
Esperion Therapeutics annual revenue
Esperion Therapeutics annual revenue over time
| Fiscal year / year | Esperion Therapeutics revenue |
|---|---|
| 2019 | $148.4M |
| 2020 | $227.5M |
| 2021 | $78.4M |
| 2022 | $75.5M |
| 2023 | $116.3M |
| 2024 | $332.3M |
Rate Esperion Therapeutics' financial transparency
Esperion Therapeutics annual growth
Esperion Therapeutics saw the greatest revenue growth in 2020, when revenue increased by 53.37%.
Esperion Therapeutics had the lowest revenue growth in 2021, when revenue changed by -65.52%.
Esperion Therapeutics annual growth rate over time
| Year | Esperion Therapeutics growth |
|---|---|
| 2020 | 53%↑ |
| 2021 | -66%↓ |
| 2022 | -4%↓ |
| 2023 | 54%↑ |
| 2024 | 186%↑ |
Esperion Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Esperion Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | $145.4M | $982,000 | $981,000 | $982,000 |
| 2020 | $1.8M | $212.2M | $3.8M | $9.6M |
| 2021 | $8.0M | $40.7M | $14.4M | $15.4M |
| 2022 | $18.8M | $18.8M | $19.0M | $18.8M |
| 2023 | $24.3M | $25.8M | $34.0M | $32.3M |
| 2024 | $137.7M | $73.8M | $51.6M | $69.1M |
Esperion Therapeutics jobs nearby
Do you work at Esperion Therapeutics?
Did Esperion Therapeutics meet its revenue projections?
Esperion Therapeutics financial information
| CEO | Sheldon Koenig |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 218 |
| Date Founded | 2008 |
| Headquarters | Ann Arbor, Michigan |
| Number of Locations | 1 |
| Revenue | $332.3M |
| Net Income | -$233,659,000 |
| Gross Proft | $263.7M (2024) |
| PE Ratio | -20.68 |
| Market Capitalization | $1.1B |
| Total Assets | $247,939,000 |
| Ticker | ESPR |
Esperion Therapeutics jobs you might like
Esperion Therapeutics financing
Esperion Therapeutics received early financing of $22.8M on 2008-05-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $22.8M | 05/2008 |
| Series Unknown | $33M | 04/2013 |
| Post Ipo Equity | $91.6M | 10/2014 |
| Post Ipo Equity | $189.9M | 03/2015 |
| Post Ipo Equity | $151.9M | 08/2017 |
| Post Ipo Equity | $50M | 04/2021 |
| Post Ipo Equity | $225M | 12/2021 |
Esperion Therapeutics investors
| Investors | Security type |
|---|---|
| Arboretum Ventures | Series A |
| Alta Partners | Series A |
| Domain Associates | Series A |
| Aisling Capital | Series A |
| Arboretum Ventures | Series Unknown |
| Longitude Capital | Series Unknown |
| Alta Partners | Series Unknown |
| Asset Management Ventures | Series Unknown |
| Domain Associates | Series Unknown |
| Aisling Capital | Series Unknown |
| Oberland Capital | Post Ipo Equity |
Esperion Therapeutics competitors
Esperion Therapeutics's top competitor, Merck, earned an annual revenue of $64.2B.
Esperion Therapeutics's smallest competitor is Nektar Therapeutics with revenue of $98.4M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Merck | $90,328 | $64.2B | 74,000 | 2,473 |
| Nektar Therapeutics | $83,561 | $98.4M | 718 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 758 |
| Cubist Pharmaceuticals | $91,725 | $926.4M | 873 | - |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 120 |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | - |
| Zoetis | $87,092 | $9.3B | 11,300 | 222 |
| Regeneron | $85,589 | $14.2B | 9,123 | 330 |
| SIGA Technologies | $71,494 | $115.5M | 43 | 1 |
| Seagen | $85,008 | $2.0B | 900 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Esperion Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Esperion Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Esperion Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Esperion Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Esperion Therapeutics. The data presented on this page does not represent the view of Esperion Therapeutics and its employees or that of Zippia.
Esperion Therapeutics may also be known as or be related to Esperion Therapeutics, Esperion Therapeutics Inc, Esperion Therapeutics Inc., Esperion Therapeutics, Ann Arbor, Mi and Esperion Therapeutics, Inc.